PAVmed Announces Pricing of $45 Million Public Offering of Common Stock
23 févr. 2021 09h00 HE
|
PAVmed Inc.
NEW YORK, Feb. 23, 2021 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical device company, today...
PAVmed Announces Proposed Public Offering of Common Stock
22 févr. 2021 16h13 HE
|
PAVmed Inc.
NEW YORK, Feb. 22, 2021 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical device company, today...
PAVmed Provides Business Update and Preliminary Fourth Quarter 2020 Financial Results
22 févr. 2021 08h18 HE
|
PAVmed Inc.
Announces majority-owned subsidiary Lucid Diagnostics intends to spin-off into a separate public company Lucid Diagnostics to launch major new multi-channel commercialization initiative for its...
PAVmed Reschedules Business Update Conference Call on February 22, 2021 to 8:30 AM EST
18 févr. 2021 09h30 HE
|
PAVmed Inc.
Conference call and live webcast was previously scheduled for 4:30 PM EST Lucid Diagnostics strategic advisor and medical diagnostics pioneer Stanley Lapidus to join call NEW YORK, Feb. 18, 2021 ...
First U.S. Patient Undergoes Successful Minimally Invasive Carpal Tunnel Release Using PAVmed’s CarpX® Device
16 févr. 2021 09h30 HE
|
PAVmed Inc.
NEW YORK, Feb. 16, 2021 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical technology company, today...
PAVmed to Hold Business Update Conference Call on February 22, 2021
09 févr. 2021 09h30 HE
|
PAVmed Inc.
NEW YORK, Feb. 09, 2021 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical device company, today...
PAVmed Closes $13.4 Million Common Stock Registered Direct Offering Priced At-the-Market under Nasdaq Rules
08 janv. 2021 10h53 HE
|
PAVmed Inc.
NEW YORK, Jan. 08, 2021 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical device company, today...
PAVmed Announces Registered Direct Offering of its Common Stock Priced At-the-Market under Nasdaq Rules
06 janv. 2021 09h29 HE
|
PAVmed Inc.
NEW YORK, Jan. 06, 2021 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical device company, today...
PAVmed Closes Additional $8.1 Million Common Stock Registered Direct Offering
22 déc. 2020 12h04 HE
|
PAVmed Inc.
NEW YORK, Dec. 22, 2020 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical device company, today...
PAVmed Announces Pricing of Additional $8.1 Million Common Stock Registered Direct Offering
18 déc. 2020 09h29 HE
|
PAVmed Inc.
NEW YORK, Dec. 18, 2020 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical device company, today...